Hepatitis C virus testing of persons born during 1945-1965: Recommendations from the centers for disease control and prevention

Annals of Internal Medicine

Volumn 157, Issue 11, 2012, Pages 817-822

  Smith, Bryce D ^a   Morgan, Rebecca L ^a   Beckett, Geoff A ^a   Falck Ytter, Yngve ^a   Holtzman, Deborah ^a   Ward, John W ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL CONSUMPTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROLOGY; SYSTEMATIC REVIEW; UNITED STATES; AGED; ALCOHOLISM; ARTICLE; BLOOD; MASS SCREENING; MIDDLE AGED; PATIENT EDUCATION; RISK FACTOR;

ANTIVIRUS AGENT; HEPATITIS C ANTIBODY;

AGED; ALCOHOL-RELATED DISORDERS; ANTIVIRAL AGENTS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MASS SCREENING; MIDDLE AGED; RISK FACTORS;

EID: 84870405295     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-157-9-201211060-00529     Document Type: Review

References (41)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714. [PMID: 16702586]
2. Centers for Disease Control and Prevention. Viral Hepatitis Surveillance, United States 2010. 2012:1-71. Accessed at www.cdc.gov/hepatitis/Statistics /2010Surveillance/Commentary.htm on 10 July 2012.
3. Freeman RB Jr, Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant. 2008;8:958-976. [PMID: 18336699]
4. Sanyal AJ; Governing Board the Public Policy, Clinical Practice, Manpower committees of the AASLD. The Institute of Medicine report on viral hepatitis: a call to action. Hepatology. 2010;51:727-728. [PMID: 20198626]
5. Velázquez RF, Rodríguez M, Navascués CA, Linares A, Pérez R, Sotorríos NG, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology. 2003;37:520-527. [PMID: 12601348]
6. Yang JD, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:64-70. [PMID: 20831903]
7. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007;37 Suppl 2:S88-S94. [PMID: 17877502]
8. Eheman C, Henley SJ, Ballard-Barbash R, Jacobs EJ, Schymura MJ, Noone AM, et al. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity [Editorial]. Cancer. 2012;118:2338-2366. [PMID: 22460733]
9. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156:271-278. [PMID: 22351712]
10. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis. 2011;43: 66-72. [PMID: 20739252]
11. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138: 513-521, 521.e1-6. [PMID: 19861128]
12. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47(RR-19):1-39. [PMID: 9790221]
13. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR Recomm Rep. 1999;48(RR-10):1-59, 61-66. [PMID: 10499670]
14. Roblin DW, Smith BD, Weinbaum CM, Sabin ME. HCV screening practices and prevalence in an MCO, 2000-2007. Am J Manag Care. 2011;17:548-555. [PMID: 21851142]
15. Southern WN, Drainoni ML, Smith BD, Christiansen CL, McKee D, Gifford AL, et al. Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. J Viral Hepat. 2011;18:474-481. [PMID: 20497311]
16. Spradling PR, Rupp L, Moorman AC, Lu M, Teshale EH, Gordon SC, et al; The Chronic Hepatitis Cohort Study (CHeCS) Investigators. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis. 2012;55:1047-1055. [PMID: 22875876]
17. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50:1750-1755. [PMID: 19824079]
18. Shehab TM, Sonnad S, Gebremariam A, Schoenfeld P. Knowledge of hepatitis C screening and management by internal medicine residents: trends over 2 years. Am J Gastroenterol. 2002;97:1216-1222. [PMID: 12014731]
19. Shehab TM, Sonnad SS, Jeffries M, Gunaratnum N, Lok AS. Current practice patterns of primary care physicians in the management of patients with hepatitis C. Hepatology. 1999;30:794-800. [PMID: 10462388]
20. Hagan H, Campbell J, Thiede H, Strathdee S, Ouellet L, Kapadia F, et al. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep. 2006;121:710-719. [PMID: 17278406]
21. Smith B, Patel N, Beckett G, Ward J. Comparison of hepatitis C virus infection screening strategies: elevated alanine aminotransferase levels versus birth cohort [Abstract]. Presented at The Liver Meeting, San Francisco, California, 4-8 November 2011. Abstract 394.
22. Zapata R. Clinical approach to the patient with chronic hepatitis C infection and normal aminotransferases. Ann Hepatol. 2010;9 Suppl:72-79. [PMID: 20714000]
23. Ferrante JM, Winston DG, Chen PH, de la Torre AN. Family physicians' knowledge and screening of chronic hepatitis and liver cancer. Fam Med. 2008; 40:345-351. [PMID: 18465284]
24. Napper LE, Fisher DG, Reynolds GL, Johnson ME. HIV risk behavior self-report reliability at different recall periods. AIDS Behav. 2010;14:152-161. [PMID: 19475504]
25. Smith BD, Patel N, Beckett GA, Jewett A, Ward JW. Hepatitis C virus antibody prevalence, correlates and predictors among persons born from 1945 through 1965, United States, 1999-2008 [Abstract]. Presented at The Liver Meeting, San Francisco, California, 4 - 8 November 2011. Abstract 241.
26. Westin J, Lagging LM, Spak F, Aires N, Svensson E, Lindh M, et al. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat. 2002;9:235-241. [PMID: 12010513]
27. Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61(RR-4):1-32. [PMID: 22895429]
28. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-926. [PMID: 18436948]
29. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-562. [PMID: 10451460]
30. McQuillian GM, Kruszon-Moran D, Denniston MM, Hirsch R. Viral hepatitis. NCHS Data Brief. 2010:1-8. [PMID: 20223109]
31. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al; SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376:705-716. [PMID: 20692693]
32. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-1206. [PMID: 21449783]
33. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al; PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839-1850. [PMID: 19403903]
34. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al; PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827-1838. [PMID: 19403902]
35. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-2416. [PMID: 21696307]
36. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9:509-516.e1. [PMID: 21397729]
37. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005;41:790-800. [PMID: 15791608]
38. Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156:263-270. [PMID: 22056542]
39. Kaner EF, Beyer F, Dickinson HO, Pienaar E, Campbell F, Schlesinger C, et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev. 2007:CD004148. [PMID: 17443541]
40. U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: recommendation statement. Ann Intern Med. 2004;140:462-464. [PMID: 15023712]
41. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Mahwah, NJ: Lawrence Erlbaum Associates; 1998.